Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.

导出原文传递

翻译打印收藏纠错

作者： Karen Louise,Højholt ^[1] ; Henrik,Gregersen ^[2] ; Agoston Gyula,Szabo ^[3] ; Tobias Wirenfeldt,Klausen ^[4] ; Mette Bøegh,Levring ^[5] ; Birgitte,Preiss ^[6] ; Carsten,Helleberg ^[4] ; Marie Fredslund,Breinholt ^[7] ; Emil,Hermansen ^[8] ; Lise Mette,Rahbek Gjerdrum ^[9] ; Søren Thorgaard,Bønløkke ^[10] ; Katrine,Nielsen ^[11] ; Eigil,Kjeldsen ^[11] ; Katrine Fladeland,Iversen ^[11] ; Elena Manuela,Teodorescu ^[3] ; Eva,Kurt ^[2] ; Casper,Strandholdt ^[12] ; Mette Klarskov,Andersen ^[13] ; Annette Juul,Vangsted ^[14]

作者单位： Department of Haematology, Rigshospitalet, Copenhagen University, Denmark. ^[1] Department of Haematology, Aalborg University Hospital, Aalborg, Denmark. ^[2] Department of Haematology Vejle, Hospital, Vejle, Denmark. ^[3] Department of Haematology Herlev, University Hospital, Herlev, Denmark. ^[4] Department of Haematology, Odense University Hospital, Odense, Denmark. ^[5] Department of Pathology, Odense University Hospital, Odense, Denmark. ^[6] Department of Pathology, Herlev University Hospital, Herlev, Denmark. ^[7] Department of Haematology, Zealand University Hospital, Roskilde, Denmark. ^[8] Department of Pathology, Zealand University Hospital, Roskilde, Denmark. ^[9] Department of Clinical Medicine, University of Copenhagen, Denmark. ^[10] Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. ^[11] Department of Haematology, Regionshospitalet Holstebro, Holstebro, Denmark. ^[12] Department of Haematology, Esbjerg Hospital, Esbjerg, Denmark. ^[13] Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark. ^[14]

关键词 carfilzomib daratumumab multiple myeloma real-world evidence